Weighing Transcatheter Aortic Valve Replacement vs Surgical Aortic Valve Replacement for Native Aortic Regurgitation

Dedicated devices for transcatheter aortic valve replacement (TAVR) in pure aortic regurgitation (AR) patients remain an unmet need. Despite this, off-label TAVR with commercially approved devices has been used successfully for treatment of AR in high- or extreme-risk patients. However, the data that inform our understanding of outcomes with TAVR in AR originate from small studies or registries. The lack of calcium in pure AR makes device anchoring challenging, increasing the risk of device migration, embolization, and peridevice regurgitation. 1 Yoon S.-H. Schmidt T. Bleiziffer S. et al. Transcatheter aortic valve replacement in pure native aortic valve regurgitation. J Am Coll Cardiol. 2017; 70: 2752-2763 Crossref PubMed Scopus (154) Google Scholar Little is known about the direct comparison between TAVR and surgical AVR (SAVR) in this population. Transcatheter vs Surgical Aortic Valve Replacement in Pure Native Aortic RegurgitationThe Annals of Thoracic SurgeryVol. 115Issue 4PreviewPatients with pure native aortic regurgitation (AR) have been excluded from transcatheter aortic valve replacement (TAVR) trials. We sought to examine midterm outcomes with TAVR in AR compared with surgical AVR (SAVR) in a contemporary cohort. Full-Text PDF